The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Company plans to create 100 manufacturing jobs and up to 1,000 construction jobs
Results demonstrate favorable safety profile and clinically meaningful improvements in patients with non-ischemic heart failure
Advancing toward Phase 2a evaluation in chemotherapy-related pain, a condition with no approved treatments and potential for FDA Fast Track designation
Medherant’s testosterone TEPI Patch could become the first-in-class testosterone patch developed specifically for women
Arora brings over 30 years of experience in the pharmaceutical and healthcare industry
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The acquisition will follow the planned separation of Avidity’s early-stage precision cardiology programs into a new, independent company
Subscribe To Our Newsletter & Stay Updated
